NEW YORK--(BUSINESS WIRE)--The Law Offices of Vincent Wong are investigating the Board of Directors of SteadyMed Ltd. (“SteadyMed” or the “Company”) (NASDAQGM: STDY) for possible breaches of fiduciary duty and other violations of state law in connection with the sale of the Company to United Therapeutics Corporation. Under the terms of the deal, SteadyMed stockholders will receive $4.46 per share in cash, with an additional $2.63 per share in cash upon achievement of a certain milestone related to SteadyMed’s Trevyent drug-device combination product.
The investigation concerns whether the SteadyMed Board of Directors breached their fiduciary duties to SteadyMed stockholders by failing to adequately shop the Company before entering into this transaction and whether United Therapeutics Corporation is underpaying for SteadyMed shares, thus unlawfully harming SteadyMed stockholders.
If you own common stock in SteadyMed and wish to obtain additional information, please contact Vincent Wong, Esq. either via email email@example.com, by telephone at 212.425.1140, or http://docs.wongesq.com/STDY-Info-Request-Form-1909.
Vincent Wong, Esq. is an experienced attorney that has represented investors in securities litigations involving financial fraud and violations of shareholder rights. Attorney advertising. Prior results do not guarantee similar outcomes.